Non-Hodgkin's Lymphoma Clinical Trials

A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 318 clinical trials
Featured trial
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a treatment option for adult participants with R/R …

  • 0 views
  • 25 May, 2022
  • 25 locations
Featured trial
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).  

lymphomas
lymphoma
b-cell lymphoma
  • 95 views
  • 10 May, 2022
  • 2 locations
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This is an open-label, nonrandomized, Phase 1/2 study to evaluate the safety and tolerability, the PK, the PD, and the efficacy (antianemic activity) of INCB000928 administered alone or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally …

anemia
  • 81 views
  • 10 May, 2022
  • 2 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

vasectomy
erythropoietin
epoetin alfa
cancer
  • 52037 views
  • 18 Apr, 2022
  • 9 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
  • 22909 views
  • 04 May, 2022
  • 10 locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

acalabrutinib
rituximab
cyclin d1
bendamustine
  • 1313 views
  • 14 May, 2022
  • 25 locations
  • 0 views
  • 23 Apr, 2022
  • 1 location
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

blood transfusion
  • 0 views
  • 11 May, 2022
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma

  • 0 views
  • 23 Apr, 2022
  • 1 location
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

This phase II trial studies how well anakinra works in decreasing the occurrence of cytokine release syndrome (CRS) and damage to the nerves (neurotoxicity) in patients with B-cell non-Hodgkin

cell therapy
  • 0 views
  • 09 Apr, 2022
  • 1 location